ArticleJournal of translational medicine2025
Serum TSP-1 is a useful biomarker in severity assessment and the diagnosis of osteoarthritis.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Machine Learning-Based Identification of Molecular Signatures in PTOA Cell Subtypes via Single-Cell Transcriptomics in a Mouse Model.Stem cell reviews and reports · 2026Article
- Methodological considerations on "Serum TSP-1 is a useful biomarker in severity assessment and the diagnosis of osteoarthritis".Journal of translational medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
objectiveOsteoarthritis (OA) is a degenerative joint disease characterized by articular cartilage degradation. Thrombospondin-1 (TSP-1) is a secreted trimeric glycoprotein with multiple functions. It can bind to various cell-surface receptors and is downregulated in OA chondrocytes. However, the utility of TSP-1 as a biomarker for OA remains unclear. Therefore, we aimed to investigate the association between serum TSP-1 concentration and knee OA.
designWe quantified serum TSP-1 concentrations in mice with post-traumatic OA (PTOA) and age-dependent OA (ADOA) using enzyme-linked immunosorbent assay (ELISA). We statistically analyzed the correlation between TSP-1 concentration and OA severity. Additionally, we generated cartilage-specific TSP-1 knockout mice and assessed TSP-1 concentration in the serum. Finally, we measured the concentrations of TSP-1 in the serum and synovial fluid of patients with OA and conducted statistical analyses to evaluate the correlation between TSP-1 concentration and Outerbridge grading. ROC curve analysis was used to determine the diagnostic value of TSP-1 for OA.
resultsSerum TSP-1 concentration was reduced in wild-type mice with PTOA or ADOA and negatively correlated with OA severity. In cartilage-specific TSP-1 knockout mice, serum TSP-1 levels were decreased. In patients with OA, serum and synovial fluid TSP-1 levels were reduced and negatively correlated with OA severity. These findings suggest that TSP-1 may serve as a potential biomarker for the diagnosis of OA.
conclusionSerum TSP-1 concentration is associated with OA severity in both mice and humans and may serve as a useful diagnostic biomarker for OA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.